GlaxoSmithKline's Shingrix shortage expected to persist 'throughout 2019'

GlaxoSmithKline is working to boost supply for its shingles vaccine. (Eric Sagonowsky)

In the face of "unprecedented" demand for its shingles vaccine, GlaxoSmithKline is doing everything it can to boost supply. But in spite of those effortsit shipped as much vaccine in the third quarter as it did in the first half of the yearGSK says the Shingrix shortage will persist into 2019.

Over the next two to three years, the company intends to significantly boost shipments to the U.S., with plans to grow its overall capacity to the "high teen millions" annually, spokesman Sean Clements said.

But for now, the unexpected uptake for the vaccine in the U.S. has overwhelmed the company's ability to keep up, forcing it to take steps like implementing order limits and delaying TV advertising.

Infographic Download

Reducing Time to Clinic for Your Biomedical Applications

Gelatin methacryloyl (GelMA)-based biomaterials have been widely used in various biomedical research applications due to their suitable biological properties and tunable physical characteristics. Especially over the past 5 years, GelMA-oriented research and patent applications have been growing exponentially, and many of these research concepts are now being translated towards the clinic. Suitable GelMA biomaterials are therefore indispensable to keep pace with the newest medical innovations.

Download today and learn more about the benefits of GelMA in various biomedical applications and how X-Pure® GelMA can help you in your developments.

“Because healthcare professionals continue to vaccinate at a rate many times that of previous years, we expect ordering limits to continue throughout 2019 to help us ensure that vaccine is distributed fairly and equitably where it is needed,” Clements added.

RELATED: GlaxoSmithKline's Shingrix zooms toward blockbuster status despite tight supply

GSK makes the shots, which take 6 to 9 months to produce, at a plant in Belgium. In the face of an expected approval, GSK had stockpiled some "critical elements" to shorten production timelines after approval. Even with that effort, the company hasn't been able to keep up with demand. For consumers, the shortage means pharmacies have long wait lists or no wait lists at all, according to reports.

GlaxoSmithKline's new shingles vaccine won U.S. approval last fall and has surpassed early sales estimates. About 7 million doses had been administered as of September. For 2018, the company is expecting £700 million to £750 million in sales for Shingrix.

RELATED: GlaxoSmithKline limits Shingrix orders, delays TV commercials amid 'unprecedented' demand

The vaccine supplanted Merck's Zostavax on the market and has seen higher demand than its predecessor due to its strong efficacy. Plus, U.S. vaccine advisers recommended Shingrix for people 50 and older, giving GSK a target population of 115 million adults, executives have said.

“We need to get the supply expanded as fast as possible, because we can pretty much sell anything that we can make now in the U.S.," GSK’s Luke Miels, global pharmaceuticals president, told analysts on the company's third-quarter conference call.  

As the shortage continues, GSK has held off on TV advertising for the product.

Suggested Articles

BMS’s Opdivo has plenty of competition in its current bladder cancer indication—so it’s hoping to strike out on its own in a new area of the disease.

The Japanese approval, under the brand name Jyseleca, came a month after an FDA complete response letter that asked Gilead for more data.

The Trump Administration has opened the doors for Florida and other states to import prescription drugs from Canada—despite industry objections.